简介:AIM:Tofindouttheoutcomeoflaserphotocoagulationinclinicallysignificantmacularedema(CSME)byopticalcoherencetomography(OCT).·METHODS:Itwasaprospective,non-controlled,caseseriesstudyenrolling81eyesof64patientswithCSMEbetweenAugust2008andJanuary2010.AllpatientsreceivedmodifiedgridphotocoagulationwithfrequencydoubledNd:YAGlaser.Eachpatientwasevaluatedintermsofbest-correctedvisualacuity(BCVA)andregressionorprogressionofmaculopathyafterlasertherapyat1,3and6months.Spearman’scorrelationtestwasusedtoshowthecorrelationbetweenBCVAandtotalmacularvolume(TMV).Analysisofvariance(ANOVA)wasusedtocompareamonggroupsandindependentt-testwasusedtocompareineachgroup.·RESULTS:ThereishighcorrelationbetweenBCVAandTMV(P≤0.001).BCVAimprovedin50.6%,remainedstaticin39.5%anddeterioratedin9.9%patientsafter6monthoftreatment.TheBaselineTMV(meanandSD)were9.26±1.83,10.4±2.38,11.5±3.05,8.89±0.75and9.47±1.98mm3fordifferentOCTpatterns,ST(spongelikethickening),CMO(cystoidmacularedema),SFD(subfovealdetachment),VMIA(Vitreomacularinterfaceabnormality)andaverageTMVrespectively(P=0.04).After6monthsoflasertreatment,themeanTMVdecreasedfrom9.47±1.98mm3to8.77±1.31mm3(P=0.01).InSTtherewassignificantdecreaseinTMV,P=0.01,Furtherwithinthesegroupsat6months,theyweresignificantlydifferent,P=0.01.·CONCLUSION:OCTshowedthedifferentmorphologicalvariantofCSMEwhiletheresponseoftreatmentisdifferent.TMVdecreasedthemostandhenceshowedtheimprovementinvisionafter6monthsoflasertreatment.IntheeraofAntivascularendothelialgrowthfactors(VEGFs),efficacyoflaserseemstobeinshadowbutitisstillfirstlineoftreatmentindevelopingnationlikeNepalwhereantiVEGFsmaynotbeeasilyavailableandaffordable.
简介:目的通过观察中药川芎嗪联合西药氨基胍治疗对糖尿病早期大鼠视网膜组织醛糖还原酶(aldosereductase,AR)和一氧化氮合酶(nitricoxidesynthase,NOS)含量的影响,探讨中西药治疗糖尿病视网膜病(dirabeticretinopathy,DR)的治疗机制.方法选择健康成年雄性SD大鼠,随机分成正常对照组、糖尿病组、糖尿病川芎嗪治疗组、糖尿病氨基胍治疗组和糖尿病川芎嗪联合氨基胍治疗组.一次性腹腔注射链脲佐菌素(streptozotocin,STZ)诱发糖尿病模型,于第90d测定各组大鼠视网膜组织AR和NOS含量.结果糖尿病川芎嗪治疗组、糖尿病氨基胍治疗组和糖尿病川芎嗪联合氨基胍治疗组的大鼠视网膜组织AR和NOS含量低于糖尿病组、糖尿病川芎嗪联合氨基胍治疗组的大鼠视网膜组织AR和NOS含量低于糖尿病川芎嗪治疗组和糖尿病氨基胍治疗组.结论结合以往观察的川芎嗪联合氨基胍治疗对大鼠眼底和视网膜组织学的影响结果,川芎嗪和氨基胍可通过降低糖尿病早期大鼠视网膜AR和NOS含量而防治DR,联合用药效果更佳.
简介:AIM:Tostudyclinicalfeaturesandgenemutationswithinthepaired-likehomeodomaintranscriptionfactor2(PITX2)geneinapedigreeofbilaterallimbaldermoids.METHODS:Completeeyeexaminationshavebeenperformedoneachindividualofthefamily.Exonsofpaired-likehomeodomaintranscriptionfactor2(PITX2)wereamplifiedbypolymerasechainreaction,sequenced,andcomparedwithareferencedatabase.RESULTS:Wedescribedthephenotype,clinicfindingsinafamilywithtwoaffectedmembers.Themassesoftheproband’seyeswereexcisedsurgicallydemonstratingadermoidcystbyhistopathologicalexamination.NomutationwasdetectedinthegenePITX2inthispedigree.CONCLUSION:Afamilyoflimbaldermoidcystwasreported.Inaddition,nopathogenicsequencevariationswerefoundinPITX2,indicatingthatthisphenotypeinthisfamilyisadistinctiveentity.
简介:AIM:Topresenttheoutcomeofmodifiedgridlaserphotocoagulation(GLP)indiffusediabeticmacularedema(DDME)ineyeswithoutextrafovealand/orvitreofovealtraction.METHODS:InclusioncriteriafortheretrospectivestudywereDDMEeyesofpatientswithtypeⅡdiabetesmellitusthathad≥4monthsoffollow-upfollowingGLP.Onlyoneeyeperpatientwasanalyzed.Using3-Dspectral-domainopticalcoherencetomography(3-DSDOCT),eyesthathadeitherextrafovealorvitreofovealtraction,orhadbeenpreviouslytreatedbyanintravitrealmedication(s)wereexcluded.TreatedDDMEeyesweredividedinto4groups:A)'Classic'DDMEthatinvolvedthecentralmacula;B)edemadidnotinvolvethemacularcenter;C)eyesassociatedwithcentralepiretinalmembrane(ERM);D)DDMEthatwasassociatedwithmacularcapillarydropout≥2disc-diameter(DD).RESULTS:GLPoutcomein35DDMEeyesafter4-24(mean,13.1±6.9)monthswasasfollows:GroupA)18eyeswith'classic'DDME.Followingoneor2(mean,1.2)GLPtreatments,best-correctedvisualacuity(BCVA)improvedby1-2Snellenlinesin44.4%(8/18)ofeyes,andworsenedby1linein11.1%(2/18).Centralmacularthickness(CMT)improvedby7%-49%(mean,26.6%)in77.8%(14/18)ofeyes.CausesofCMTworsening(n=4)werecommonlyexplainable,predominantly(n=3)associatedwithemergenceofextrafovealtraction,5-9monthspost-GLP.GroupB)GLP(s)inDDMEthatdidnotinvolvethemacularcenter(n=6)resultedinimprovedBCVAby1-2linesin2eyes.However,thecentralmaculabecameinvolvedintheedemaprocessaftertheGLPin3(50%)eyes,associatedwithanemergenceofextrafovealtractioninoneoftheseeyes4monthsfollowingtheGLP.GroupC)GLPfailedinall5eyesassociatedwithcentralERM.GroupD)GLPwasofpartialbenefitin2of6treatedeyeswithmacularcapillarydropout≥2DD.CONCLUSION:EyeswithDDMEthatinvolvedthemacularcenterwerefoundtoachievefavourableoutcomesafterGLP(s)duringmid-termfollow-up,unlesscomplicatedpre-GLPorpost-GLPbyvltreoretinalinterfaceabnormalities,oftenextrafovealtra
简介:目的:对比23G和25G+微创玻璃体切割术对增生性糖尿病视网膜病(proliferativediabeticretinopathy,PDR)的治疗效果。方法:选取2013-11/2016-05于我院眼科行玻璃体切割术治疗的128例195眼PDR患者,随机分为两组,25G+组64例97眼,23G组64例98眼。25G+组应用25G+玻璃体切割术,23G组应用23G玻璃体切割术。两组患者术后随访时间分别为1d,1wk,1mo。比较两组手术时间,术前及术后的眼压、最佳矫正视力及医源性损伤、并发症发生情况。结果:25G+组手术时间短于23G组(P〈0.05);两组患者术后1mo的视力分布均显著优于本组术前的视力分布(P〈0.01);两组同期的视力分布没有统计学差异(P〉0.05)。25G+组术前的眼压分别与手术1d,1wk,1mo的眼压比较,差异均没有统计学意义(P〉0.05);23G组亦然。两组同期的眼压比较也无统计学差异(P〉0.05)。25G+组的医源性损伤率为4.1%,显著低于23G组的13.3%,差异有统计学意义(P〈0.05)。25G+组的术后并发症发生率为3.1%,显著低于23G组的11.2%,差异有统计学意义(P〈0.05)。结论:23G和25G+玻璃体切割术均可安全有效地治疗PDR,但是25G+微创玻璃体切割术在缩短手术时间、减少医源性损伤及并发症发生率方面显示出更好的优势,是治疗PDR的更好选择。
简介:AIM:Todescribethedesignandpreliminaryresultsofthehospitalbasedepidemiologicalstudyfordiabeticretinopathy(HBESDR),anongoingepidemiologicalstudytoestimatetheprevalenceofdiabeticretinopathy(DR)andtoelucidatetheclinical,anthropometric,biochemicalandanyotherriskfactorsassociatedwithdiabeticretinopathy.METHODS:Totally2000diabeteswillberecruitedfromtheDiabeteseyeclinicintheFirstAffiliatedHospitalofChinaMedicalUniversity.AllsubjectsunderwentbloodsugarestimationandOralGlucoseToleranceTesttodiagnosediabetes.Alldiabeteswouldundergocompletequestionnaire,acomprehensiveeyeexamination.Bloodandurinewouldbecollectedforbiochemicalinvestigations.AllfundusphotographsforanyDRwillbegraded.Participantswhoneedtreatmentwillbesenttotheophthalmicclinicandfollow-upintervalprogramforallsubjectswillbesuggested.Acomputerizeddatabaseiscreatedfortherecords.RESULTS:Todate,1174diabeteshavebeenrecruited,therewere350(29.81%)DRinalldiabetes,mostofthemwerewithmildnon-proliferativediabeticretinopathy(NPDR)(139,39.71%);71(20.29%)moderateNPDR,66(18.86%)severeNPDR,74(21.14%)proliferativediabeticretinopathy(PDR).Females,longerdurationofdiabetes,familyhistoryofdiabetesandhypertensionhadastatisticallysignificantincreaseinriskofanyDR.CONCLUSION:ThestudyisexpectedtoprovideanestimateoftheoverallprevalenceofDRandtheprevalencewithdifferentdurationofdiabetesandalsoabetterunderstandingoftheriskfactorsassociatedwithDR.
简介:<正>DirSir,IamdoctorGuo-YuanYang,fromtheDepartmentofOphthalmologyofWestChinaHospitalofSichuanUniversityinChengdu,SichuanProvince,China.Iwritetopresentacasereportofposteriorlentiglobuswithcataract.
简介:<正>DearSir,IamProf.BeuyJoobfromSanitation1MedicalAcademicCenter,Bangkok,Thailand.Iwritetodiscusstherecentpublicationonproteomicanalysisindiabeticretinopathy(DR).Liuetal[1]concludedthattheirapproachbytwodimensionalfluorescencedifferencegelelectrophoresis(2D-DIGE)combinedwithmatrix-assistedlaser